At a glance
- Originator GlaxoSmithKline
- Class Antiarrhythmics; Antihistamines; Nootropics
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Cognition disorders
Most Recent Events
- 01 Nov 1999 Discontinued-Preclinical for Arrhythmias in United Kingdom (Unknown route)
- 01 Nov 1999 Discontinued-Preclinical for Cognition disorders in United Kingdom (Unknown route)
- 23 Apr 1997 No-Development-Reported for Arrhythmias in United Kingdom (Unknown route)